DPW
KYMR icon

DiNuzzo Private Wealth’s Kymera Therapeutics KYMR Stock Holding History

DiNuzzo Private Wealth’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$574 Hold
5
– – ﹤0.01% 1063
2026
Q1 		$417 Sell
5
-1
-17% -$79 ﹤0.01% 1123
2025
Q4 		$467 Buy
6
+4
+200% +$270 ﹤0.01% 1102
2025
Q3 		$83 Buy
+2
New +$90 ﹤0.01% 1317

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

DiNuzzo Private Wealth's KYMR Position: Q2 2026 in Review

DiNuzzo Private Wealth held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 5 shares worth $574. The position accounts for ﹤0.01% of the portfolio, ranked #1063.

DiNuzzo Private Wealth first reported a position in KYMR in Q3 2025 and has held it in 4 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • DiNuzzo Private Wealth held 5 shares of Kymera Therapeutics worth $574 as of Q2 2026.
  • DiNuzzo Private Wealth left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of DiNuzzo Private Wealth's portfolio in Q2 2026, its #1063 holding.
  • DiNuzzo Private Wealth first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on DiNuzzo Private Wealth's 13F filing for Q2 2026, filed 10 Jul 2026.